Drug Trial Radar · NCT03648489
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Sep 21, 2018
Primary completion
Nov 30, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- Imperial College LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Takeda Pharmaceuticals International, Inc.; North Eastern German Society of Gynaecological Oncology
- First posted
- Aug 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DICE is a randomised study recruiting 126 women over 3 years from hospitals in the UK and Germany. Eligible patients will have tissue based diagnosis of advanced/recurrent ovarian cancer (clear cell, endometrioid or high grade serous or carcinosarcoma), have had chemotherapy before, and be platinum-resistant (the cancer has returned/grown significantly during or within 6 months of platinum-containing chemotherapy).
Conditions
- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinosarcoma
- Ovarian Serous Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Clear Cell Adenocarcinoma
- Fallopian Tube Cancer
- Fallopian Tube Neoplasms
- Primary Peritoneal Carcinoma
- Primary Peritoneal Serous Adenocarcinoma
Interventions
PaclitaxelDrug
Please refer to arm/group description
TAK228Drug
Please refer to arm/group description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: 12 months
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
KEM Kliniken Essen-Mitte
Essen, Germany
Churchill Hospital
Oxford, United Kingdom
Weston Park Hospital
Sheffield, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Furness General Hospital
Barrow in Furness, Cumbria, United Kingdom
St George's University Hospitals NHS Foundation Trust
London, Greater London, United Kingdom
The Royal Marsden NHS Foundation Trust
London, Greater London, United Kingdom
Imperial College Healthcare NHS Trust
London, Greater London, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, Greater London, United Kingdom
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom
Royal Lancaster Infirmary
Lancaster, Lancashire, United Kingdom
Mount Vernon Cancer Centre
Northwood, Middlesex, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, Nottinghamshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.